SCM
PRVB

Segantii Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Segantii Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-285,000
Closed -$2.62M – 98
2020
Q1 		$2.62M Buy
285,000
+23,700
+9% +$305K 0.21% 40
2019
Q4 		$3.89M Sell
261,300
-463,400
-64% -$4.13M 0.28% 55
2019
Q3 		$4.95M Buy
+724,700
New +$7.33M 0.67% 30

Other funds holding PRVB

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segantii Capital Management's PRVB Position: Q2 2020 in Review

Segantii Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2020, closing a stake of 285,000 shares — an estimated $2.62M sold.

Segantii Capital Management first reported a position in PRVB in Q3 2019 and held it in 3 quarters. The position peaked at $4.95M in Q3 2019. 106 funds tracked by Wall St. Rank hold PRVB as of Q2 2020.

  • Segantii Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Segantii Capital Management sold 285,000 Provention Bio, Inc. Common Stock shares in Q2 2020, an estimated $2.62M.
  • Segantii Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 3 quarters.
  • Segantii Capital Management's Provention Bio, Inc. Common Stock position peaked at $4.95M in Q3 2019.
  • 106 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2020.

Based on Segantii Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.